127 related articles for article (PubMed ID: 2523809)
21. A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.
Skillings J; Cripps C; Eisenhauer E; Pater J; Verma S; Walde D
Invest New Drugs; 1991 Feb; 9(1):79-82. PubMed ID: 1827434
[TBL] [Abstract][Full Text] [Related]
22. Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University.
Cruz JM; Case LD; Dalton HB; Ramseur WL; Richards F; Jackson DV; Muss HB; Zekan PJ; Brodkin RA; Brown RC
Invest New Drugs; 1992 Apr; 10(1):35-7. PubMed ID: 1535064
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer.
Kennedy MJ; Donehower RC; Grochow LB; Ettinger DS; Fetting JH; Abeloff MD
Invest New Drugs; 1990 Aug; 8(3):289-94. PubMed ID: 2148742
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of oral menogaril administered daily for 14 consecutive days.
Stewart DJ; Aitken SE; Verma S; Maroun JA; Robillard L; Touchie M; Prosser IA; Earhart R
Ann Oncol; 1992 May; 3(5):401-3. PubMed ID: 1535508
[TBL] [Abstract][Full Text] [Related]
25. Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.
Conley BA; Egorin MJ; Sinibaldi V; Van Echo DA
Invest New Drugs; 1990 Nov; 8(4):365-7. PubMed ID: 2150671
[No Abstract] [Full Text] [Related]
26. Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
Eisenhauer EA; Pritchard KI; Perrault DJ; Verma S; Pater JL
Invest New Drugs; 1990 Aug; 8(3):283-7. PubMed ID: 2148741
[TBL] [Abstract][Full Text] [Related]
27. Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.
Vance RB; Crowley JJ; Macdonald JS; Ahmann FR
Invest New Drugs; 1991 Feb; 9(1):73-5. PubMed ID: 1851143
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Stewart DJ; Eisenhauer EA; Skillings J; Pritchard KI; Buckman R; VAndenberg T; Verma S; Aitken S; Norris B
Ann Oncol; 1992 Mar; 3(3):201-4. PubMed ID: 1534021
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.
Sternberg CN; Magill GB; Cheng EW; Hollander P
Am J Clin Oncol; 1988 Apr; 11(2):174-6. PubMed ID: 2965856
[TBL] [Abstract][Full Text] [Related]
30. Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
Dorr FA; Von Hoff DD; Kuhn JG; Schwartz R; Kisner DL
Cancer Res; 1986 May; 46(5):2562-5. PubMed ID: 2938729
[TBL] [Abstract][Full Text] [Related]
31. Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
LONG HJ; Wieand HS; Foley JF; Niedringhaus RD; Laurie JA; Morton RF; Goldberg RM; Mailliard JA; Malkasian GD; Edmonson JH
Invest New Drugs; 1991 Nov; 9(4):349-51. PubMed ID: 1839536
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of intravenous menogaril administered intermittently.
Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
[TBL] [Abstract][Full Text] [Related]
33. [Antitumor spectrum of TUT-7 on rat ascitic hepatoma].
Satoh H; Taguchi H; Yahagi S
Gan To Kagaku Ryoho; 1990 Feb; 17(2):287-91. PubMed ID: 2137321
[TBL] [Abstract][Full Text] [Related]
34. Anthracycline analogs: the past, present, and future.
Weiss RB; Sarosy G; Clagett-Carr K; Russo M; Leyland-Jones B
Cancer Chemother Pharmacol; 1986; 18(3):185-97. PubMed ID: 2948729
[No Abstract] [Full Text] [Related]
35. Menogaril: a new anthracycline agent entering clinical trials.
McGovren JP; Nelson KG; Lassus M; Cradock JC; Plowman J; Christopher JP
Invest New Drugs; 1984; 2(4):359-67. PubMed ID: 6239835
[TBL] [Abstract][Full Text] [Related]
36. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
[TBL] [Abstract][Full Text] [Related]
37. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
38. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
39. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study.
Ettinger DS; Finkelstein DM; Abeloff MD; Skeel RT; Stott PB; Frontiera MS; Bonomi PD
J Natl Cancer Inst; 1992 Jul; 84(14):1077-84. PubMed ID: 1320131
[TBL] [Abstract][Full Text] [Related]
40. Menogaril in the treatment of malignant mesothelioma: a phase II study.
Hudis CA; Kelsen DP
Invest New Drugs; 1992 Jul; 10(2):103-6. PubMed ID: 1386842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
